Dissecting dysfunctional crosstalk pathways regulated by miRNAs during glioma progression

Zhang, Yunpeng; Xu, Yanjun; Li, Xiang; Li, Feng; Shi, Xinrui; Wang, Lihua; Li, Xia

doi:10.18632/oncotarget.8265

Cited by 7 publications

(8 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hundreds of miRNAs have been identified in GBM which were up regulated or down regulated, and function as oncogenes or tumor suppressor genes via mRNA degradation or translation inhibition [ 2 , 18 , 19 ]. They target multiple signaling pathways and each miRNA regulates numerous gene expressions [ 2 , 18 , 20 ]. GBM progression has often been demonstrated to result from the dysfunctional miRNA-pathway crosstalk network [ 2 , 18 , 20 ], and cell communication related pathways, such as focal adhesion, regulation of actin cytoskeleton, and adherens junction, were involved in the miRNA regulated pathway crosstalk module [ 20 ].…”

Section: Introductionmentioning

confidence: 99%

“…They target multiple signaling pathways and each miRNA regulates numerous gene expressions [ 2 , 18 , 20 ]. GBM progression has often been demonstrated to result from the dysfunctional miRNA-pathway crosstalk network [ 2 , 18 , 20 ], and cell communication related pathways, such as focal adhesion, regulation of actin cytoskeleton, and adherens junction, were involved in the miRNA regulated pathway crosstalk module [ 20 ]. Competing endogenous RNAs (ceRNAs), which are mRNAs with competitive miRNA binding sites and are modulated by miRNAs, were predicted for four GBM signature genes ( PDGFRA , EGFR , NF1 , and PTEN ) with each of the ceRNA correlated with different GBM subtypes: ceRNAs of PDGFRA and NF1 overlapped with proneural signature genes, EGFR ceRNAs with classical signature genes, and PTEN ceRNAs with mesenchymal signatures [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

“…They are RTK/Ras/PI3K, Rb and p53 pathways [ 3 ]. Extensive investigation involving large numbers of GBM patient samples identified more signaling pathways and effectors [ 2 , 20 , 33 – 37 ] involved with GBM development, and demonstrated that different subtypes of GBM may involve different signaling pathway activation [ 2 ] (Figure 2 ).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Glioblastoma: new therapeutic strategies to address cellular and genomic complexity

Cai

Sughrue

2017

Oncotarget

View full text Add to dashboard Cite

Glioblastoma (GBM) is the most invasive and devastating primary brain tumor with a median overall survival rate about 18 months with aggressive multimodality therapy. Its unique characteristics of heterogeneity, invasion, clonal populations maintaining stem cell-like cells and recurrence, have limited responses to a variety of therapeutic approaches, and have made GBM the most difficult brain cancer to treat. A great effort and progress has been made to reveal promising molecular mechanisms to target therapeutically. Especially with the emerging of new technologies, the mechanisms underlying the pathology of GBM are becoming more clear. The purpose of this review is to summarize the current knowledge of molecular mechanisms of GBM and highlight the novel strategies and concepts for the treatment of GBM.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Glioblastoma: new therapeutic strategies to address cellular and genomic complexity

Cai

Sughrue

2017

Oncotarget

View full text Add to dashboard Cite

show abstract

“…Interestingly, the two up-regulated miRNAs (miR-15b and miR-21) have been identified as circulating markers for glioma [ 24 ]. Furthermore, miR-15b has recently been identified as a “hub” gene that regulates multiple pathways associated with glioma progression [ 12 ]. Conversely, each of the down-regulated genes has been directly shown to have tumor suppressor properties, including the ability to inhibit glioblastoma invasion, migration and viability [ 13 , 26 - 29 ].…”

Section: Discussionmentioning

confidence: 99%

The prognostic value of a seven-microRNA classifier as a novel biomarker for the prediction and detection of recurrence in glioma patients

Chen

et al. 2016

Oncotarget

View full text Add to dashboard Cite

Glioma is often diagnosed at a later stage, and the high risk of recurrence remains a major challenge. We hypothesized that the microRNA expression profile may serve as a biomarker for the prognosis and prediction of glioblastoma recurrence. We defined microRNAs that were associated with good and poor prognosis in 300 specimens of glioblastoma from the Cancer Genome Atlas. By analyzing microarray gene expression data and clinical information from three random groups, we identified 7 microRNAs that have prognostic and prognostic accuracy: microRNA-124a, microRNA-129, microRNA-139, microRNA-15b, microRNA-21, microRNA-218 and microRNA-7. The differential expression of these miRNAs was verified using an independent set of glioma samples from the Affiliated People's Hospital of Jiangsu University. We used the log-rank test and the Kaplan-Meier method to estimate correlations between the miRNA signature and disease-free survival/overall survival. Using the LASSO model, we observed a uniform significant difference in disease-free survival and overall survival between patients with high-risk and low-risk miRNA signature scores. Furthermore, the prognostic capability of the seven-miRNA signature was demonstrated by receiver operator characteristic curve analysis. A Circos plot was generated to examine the network of genes and pathways predicted to be targeted by the seven-miRNA signature. The seven-miRNA-based classifier should be useful in the stratification and individualized management of patients with glioma.

show abstract

“…Furthermore, Liu et al have established a database SM2miR [20], which provides a comprehensive resource about the influences of drugs on miRNA expression and offers unprecedented opportunities for researchers on the screening and action mechanism of drugs for disease treatment. In addition, our previous research also displays that miRNA participates in the crosstalk among pathways that play important roles in cancer development [21], indicating that it might be more effective for screening cancer treatment to evaluate the effects of drugs on the miRNA-mediated crosstalk between pathways.…”

Section: Introductionmentioning

confidence: 99%

Quantifying Risk Pathway Crosstalk Mediated by miRNA to Screen Precision drugs for Breast Cancer Patients

Lin

Zhao

et al. 2019

Genes

View full text Add to dashboard Cite

Breast cancer has become the most common cancer that leads to women’s death. Breast cancer is a complex, highly heterogeneous disease classified into various subtypes based on histological features, which determines the therapeutic options. System identification of effective drugs for each subtype remains challenging. In this work, we present a computational network biology approach to screen precision drugs for different breast cancer subtypes by considering the impact intensity of candidate drugs on the pathway crosstalk mediated by miRNAs. Firstly, we constructed and analyzed the subtype-specific risk pathway crosstalk networks mediated by miRNAs. Then, we evaluated 36 Food and Drug Administration (FDA)-approved anticancer drugs by quantifying their effects on these subtype-specific pathway crosstalk networks and combining with survival analysis. Finally, some first-line treatments of breast cancer, such as Paclitaxel and Vincristine, were optimized for each subtype. In particular, we performed precision screening of subtype-specific therapeutic drugs and also confirmed some novel drugs suitable for breast cancer treatment. For example, Sorafenib was applicable for the basal subtype treatment, Irinotecan was optimum for Her2 subtype treatment, Vemurafenib was suitable for the LumA subtype treatment, and Vorinostat could apply to LumB subtype treatment. In addition, the mechanism of these optimal therapeutic drugs in each subtype of breast cancer was further dissected. In summary, our study offers an effective way to screen precision drugs for various breast cancer subtype treatments. We also dissected the mechanism of optimal therapeutic drugs, which may provide novel insight into the precise treatment of cancer and promote researches on the mechanisms of action of drugs.

show abstract

Dissecting dysfunctional crosstalk pathways regulated by miRNAs during glioma progression

Cited by 7 publications

References 41 publications

Glioblastoma: new therapeutic strategies to address cellular and genomic complexity

Glioblastoma: new therapeutic strategies to address cellular and genomic complexity

The prognostic value of a seven-microRNA classifier as a novel biomarker for the prediction and detection of recurrence in glioma patients

Quantifying Risk Pathway Crosstalk Mediated by miRNA to Screen Precision drugs for Breast Cancer Patients

Contact Info

Product

Resources

About